An interventional study of whey protein and Placebo in Type 2 Diabetes and Shift-work Disorder, sponsored by University of Adelaide. Recruiting at 1 site in Australia. Open to female participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-24.
Sponsored by University of Adelaide · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 262 studies in Diabetes Mellitus, Type 2 with a site in Australia — 24 open to participants now, 30 under way, 13 of them phase 3. Diabetes Mellitus, Type 2 · Australia.
Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, this one is the 228th largest by planned enrollment of the 246 interventional ones that give a count, is one of 6 that started in 2021, is one of 31 with no phase, reaches primary completion later than 1 of the 29 other live ones, and was the 211th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →24 of the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Australia, United States, Canada and 3 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Bulgaria and 10 more countries
Ages 18+
AstraZeneca · Sites in Australia, United States, Argentina and 12 more countries
Ages 18+
Novo Nordisk A/S · Sites in Australia, United States, Germany and 6 more countries
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 35 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
262 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 47 · Phase 3 136 · Phase 4 22
First in 2001; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 392 across the 246 interventional studies, 911 across the 16 observational. Of the 224 that completed or were terminated, 115 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
223 of 262 have an industry lead sponsor. The 10 most frequent:
University of Adelaide is the lead sponsor of 42 studies on the registry; 6 are open to participants now.
University of Adelaide has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
9 of the studies in Diabetes Mellitus, Type 2 with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06888687Australian Catholic UniversityComparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes. | 2026-11-28 |
| NCT07228117Medtronic MiniMed, Inc.GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | 2027-01 |
| NCT06937203Arrowhead PharmaceuticalsA First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | 2027-02 |
| NCT06267391Endogenex, Inc.Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | 2027-02-01 |
| NCT07215559Eli Lilly and CompanyA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | 2027-03 |
Add all 9 to your calendar (.ics) → With an account.
Among the 262 studies in Diabetes Mellitus, Type 2 with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the effects of a whey protein supplement or a placebo consumed before the evening meal on health outcomes in night shift workers.
Participants are assigned in random order to two conditions, for 12 days each. The interventions are 1) a 30g whey protein preload consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given. 2) an identical mixed-nutrient drink matched for caloric content, taste and palatability consumed 1-1.5 hr prior to their main evening meal every day for 12 days(placebo). Conditions are separated by a 2-week washout period, during which participants will be encouraged to maintain their habitual diet and physical activity levels. Metabolic testing will be performed at baseline, and at the end of both conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will consume 30 g whey protein isolate powder (dissolved in water) 1-1.5 hr prior to their main evening meal every day for 12 days.
Dietary Supplement: whey protein
Participants will consume an energy-matched mixed-nutrient placebo drink 1-1.5 hr prior to their main evening meal every day for 12 days,
Dietary Supplement: Placebo
Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
Glycaemic response
Change in glucose (AUC) following a standard breakfast
Time frame: 12 days (3 hours meal test)
24-hour glucose profiles
Change in 24-hour glucose profiles assessed by continuous glucose monitoring
Time frame: 12 days
Glucose variability
Change in 24-hour glucose variability (as SD, standard deviation) assessed by continuous glucose monitoring
Time frame: 12 days
Glucose variability
Change in 24-hour glucose variability (as CV, coefficients of variation) assessed by continuous glucose monitoring
Time frame: 12 days
Glucose variability
Change in 24-hour glucose variability (as MAGE, mean amplitude of gylcaemic excursions) assessed by continuous glucose monitoring
Time frame: 12 days
GLP-1
Change in GLP-1 (AUC) following a standard breakfast
Time frame: 12 days (3 hours meal test)
GIP
Change in GIP (AUC) following a standard breakfast
Time frame: 12 days (3 hours meal test)
glucagon
Change in glucagon (AUC) following a standard breakfast
Time frame: 12 days (3 hours meal test)
Insulin
Change in fasting and postprandial insulin following a standard breakfast
Time frame: 12 days
Ghrelin
Change in ghrelin (AUC) following a standard breakfast
Time frame: 12 days (3 hours meal test)
PYY
Change in YY (AUC) following a standard breakfast
Time frame: 12 days
Adiponectin
Change in fasting adiponectin
Time frame: 12 days
C-Reactive Protein (CRP)
Change in fasting CRP
Time frame: 12 days
Blood lipids
Changes in blood lipid profile (total cholesterol, HDL-, LDL-cholesterol and triglycerides)
Time frame: 12 days
Blood pressure
Changes in systolic blood pressure and diastolic blood pressure
Time frame: 12 days
Resting metabolic rate
Changes in resting metabolic rate
Time frame: 12 days
respiratory quotient
Changes in respiratory quotient
Time frame: 12 days
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2021 (actual). Primary completion is estimated for Jul 2025, 51 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 51 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Whey Proteins
University of Adelaide